Amylyx Pharmaceuticals, Inc.
AMLX
$14.05
$0.261.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.61% |
| Cost of Revenue | 14.09% | -9.94% | -11.53% | -85.54% | -233.46% |
| Gross Profit | -13.29% | 8.21% | 14.38% | 65.64% | 32.48% |
| SG&A Expenses | -9.97% | -9.29% | -27.75% | -72.85% | -67.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.46% | -9.65% | -18.23% | -82.06% | -62.46% |
| Operating Income | 9.96% | 8.70% | 19.80% | 69.05% | -2,202.07% |
| Income Before Tax | 13.69% | 52.70% | 42.99% | 69.71% | -689.58% |
| Income Tax Expenses | 107.24% | -- | -- | -- | -136.39% |
| Earnings from Continuing Operations | 12.11% | 52.70% | 42.99% | 69.77% | -893.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.11% | 52.70% | 42.99% | 69.77% | -893.62% |
| EBIT | 9.96% | 8.70% | 19.80% | 69.05% | -2,202.07% |
| EBITDA | 9.87% | 8.49% | 19.75% | 69.09% | -1,911.81% |
| EPS Basic | 45.12% | 65.50% | 56.50% | 76.07% | -879.77% |
| Normalized Basic EPS | 49.99% | 31.25% | 36.55% | 76.02% | -1,263.55% |
| EPS Diluted | 45.12% | 65.50% | 56.50% | 76.07% | -888.76% |
| Normalized Diluted EPS | 49.99% | 31.25% | 36.55% | 76.02% | -1,298.40% |
| Average Basic Shares Outstanding | 60.13% | 37.07% | 31.04% | 26.30% | 1.75% |
| Average Diluted Shares Outstanding | 60.13% | 37.07% | 31.04% | 26.30% | -0.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |